Clene Inc. ( CLNN ) Reports Q2 Loss, Misses Revenue Estimates
Clene (CLNN) delivered earnings and revenue surprises of -59.18% and -73.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Mersana Therapeutics, Inc. ( MRSN ) Reports Q2 Loss, Lags Revenue Estimates
Mersana Therapeutics (MRSN) delivered earnings and revenue surprises of -8.80% and -58.90%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Fate Therapeutics ( FATE ) Reports Q2 Loss, Beats Revenue Estimates
Fate Therapeutics (FATE) delivered earnings and revenue surprises of +17.14% and +190.70%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Avidity ( RNA ) Q2 Revenue Jumps 88%
Avidity Biosciences ( NASDAQ:RNA ) , a biotechnology firm developing RNA-targeted therapeutics for rare muscle diseases, reported its second-quarter 2025 results on August 7, 2025. The period featured sharply higher revenue ( GAAP ) at $3.8 million, well above the $1.49 million average analyst ...
Iovance Biotherapeutics ( IOVA ) Reports Q2 Loss, Lags Revenue Estimates
Iovance Biotherapeutics (IOVA) delivered earnings and revenue surprises of -13.79% and -9.64%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Arcutis Biotherapeutics, Inc. ( ARQT ) Reports Q2 Loss, Beats Revenue Estimates
Arcutis Biotherapeutics (ARQT) delivered earnings and revenue surprises of +27.78% and +12.32%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Quanta Announces Leadership Team Appointment and Highlights Clinical Program Progress
- 25-year industry veteran Vanessa L. Jacoby appointed CBO and CFO, bringing financial and strategic leadership - - Enrollment initiated in dose expansion cohorts in Phase 1 clinical trial of QTX3034, an oral G12D-preferring multi-KRAS inhibitor, in patients with KRASG12D-mutant pancreatic, ...
Veritex Holdings, Sequans Communications, Canaan And Other Big Stocks Moving Higher On Monday - DeFi Technologies ( NASDAQ:DEFT ) , Canaan ( NASDAQ:CAN )
U.S. stocks were lower, with the Dow Jones index falling around 0.1% on Monday. Shares of Veritex Holdings, Inc. VBTX rose sharply during Monday's session after announcing that Huntington Bancshares will acquire them for $1.9 billion. Veritex Holdings shares jumped 22.1% to $33.52 on Monday.
Avidity Biosciences Touts Encouraging Functional Gains And Biomarker Reductions In Rare Muscular Weakness Disease Trial - Avidity Biosciences ( NASDAQ:RNA )
Del-Brax improved muscle strength, mobility, and quality of life in FSHD patients in early-stage trials. Avidity begins Phase 3 FORWARD trial as del-brax shows rapid biomarker reduction and strong safety profile. Get access to the leaderboards pointing to tomorrow's biggest stock movers.
Cytokinetics to Host Symposium on Contemporary Landscapes in Muscle Biology - Cytokinetics ( NASDAQ:CYTK )
Second Annual Muscle Biology-Focused Research Symposium Highlighting Recent Innovations in the Field
Avidity Biosciences, Inc. ( RNA ) Reports Q1 Loss, Misses Revenue Estimates
Avidity Biosciences (RNA) delivered earnings and revenue surprises of -2.27% and 46.68%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Gilead Sciences ( GILD ) Q1 Earnings and Revenues Lag Estimates
Gilead (GILD) delivered earnings and revenue surprises of -0.55% and 2.46%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Avidity Biosciences ( RNA ) Soars 11.3%: Is Further Upside Left in the Stock?
Avidity Biosciences (RNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
How to Play SRPT Stock After Patient Death Post DMD Therapy Infusion
We advise investors with a long-term horizon to remain invested in Sarepta stock, given its encouraging commercial portfolio and robust pipeline potential.
Avidity Biosciences Touts Positive Data From Early-Stage Duchenne Muscular Dystrophy Study Data, FDA Submission Expected By End Of 2025 - Avidity Biosciences ( NASDAQ:RNA )
Del-zota shows a 40% increase in exon 44 skipping and a 25% rise in dystrophin production, restoring total dystrophin up to 58% of normal. Avidity selects a 5 mg/kg dose every six weeks for BLA submission, with commercial preparations for a potential U.S. launch in progress.
Dyne Therapeutics' $4.3 Billion Peak Sales Potential? Analyst Highlights Key Strengths And Risks
BMO forecasts DYNE-101 peak global sales of $4.3 billion by 2035. Dyne plans to start a Registrational Expansion Cohort in H1 2026 for potential accelerated approval. Find out which stock just plummeted to the bottom of the new Benzinga Rankings. Updated daily-spot the biggest red flags before ...
This S&P Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Avidity Biosciences ( NASDAQ:RNA ) , Radiopharm Theranostics ( NASDAQ:RADX )
Top Wall Street analysts initiated coverage on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. BMO Capital analyst Kostas Biliouris initiated coverage on Avidity Biosciences, Inc.
Avidity Biosciences, Inc. ( RNA ) Reports Q4 Loss, Tops Revenue Estimates
Avidity Biosciences (RNA) delivered earnings and revenue surprises of 4.76% and 29.26%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic - Denali Therapeutics ( NASDAQ:DNLI )
William Blair has initiated coverage on Denali Therapeutics Inc DNLI, a company focused on developing drugs for neurodegenerative diseases. The analyst highlights that Denali is developing a specialized transport vehicle ( TV ) platform to enhance the delivery of treatments across the blood-brain ...
Biotech Stock Roundup: NVAX Q3 Results, SNDX Down on AML Data, RNA Surges on Study Data
NVAX and RNA are in the spotlight following Q3 results and study data, respectively.
RNA Stock Hits Record High on Entering the Cardiac Disease Space
Avidity Biosciences expands its pipeline to include two new drugs targeting rare genetic cardiomyopathies.
Avidity Biosciences, Inc. ( RNA ) Reports Q3 Loss, Lags Revenue Estimates
Avidity Biosciences (RNA) delivered earnings and revenue surprises of 17.72% and 67.05%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Generation Bio Co. ( GBIO ) Reports Q3 Loss, Tops Revenue Estimates
Generation Bio (GBIO) delivered earnings and revenue surprises of 17.86% and 249.24%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Avidity Biosciences, Inc. ( RNA ) to Report a Decline in Earnings: What to Look Out for
Avidity Biosciences (RNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Avidity Biosciences Zoomed to a 12% Gain This Week
The company's most promising pipeline program can continue unabated.
Goldman Sachs Bullish On Avidity Biosciences, Cites Scalable RNA Therapeutics Platform For Rare Diseases - Avidity Biosciences ( NASDAQ:RNA )
Goldman Sachs has initiated coverage on Avidity Biosciences Inc RNA based on multi-blockbuster, first-to-market commercial opportunities for its investigational candidates. Avidity Biosciences is a clinical-stage biotechnology company that develops RNA therapeutics ( antibody oligonucleotide ...
Fulcrum Therapeutics Upgraded: BofA Debates Pivotal Study Success For Losmapimod In Rare Genetic Muscle Disease - Fulcrum Therapeutics ( NASDAQ:FULC )
BofA Securities has upgraded Fulcrum Therapeutics FULC ahead of the company's phase 3 losmapimod readout, expected by the end of October for Facioscapulohumeral muscular dystrophy ( FSHD ) . FSHD is a rare genetic muscle disease affecting a child's facial muscles, shoulders, upper arms, and ...
Company News for Aug 13, 2024
Companies in The News Are: ...
Avidity Biosciences, Inc. ( RNA ) Reports Q2 Loss, Misses Revenue Estimates
Avidity Biosciences (RNA) delivered earnings and revenue surprises of 14.47% and 71.16%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Expedia Posts Upbeat Earnings, Joins Akamai Technologies, Trade Desk, DXC Technology And Other Big Stocks Moving Higher On Friday - Expedia Group ( NASDAQ:EXPE )
U.S. stocks were mixed, with the Dow Jones index gaining around 0.1% on Friday. Shares of Expedia Group, Inc. EXPE rose sharply during Friday's session after the company reported better-than-expected second-quarter financial results.
Crinetics Pharmaceuticals, Inc. ( CRNX ) Reports Q2 Loss, Misses Revenue Estimates
Crinetics Pharmaceuticals (CRNX) delivered earnings and revenue surprises of -9.30% and 70.79%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
3 Russell 2000 Growth Stocks That Could Be Worth the Risk
These three small-cap stocks could deliver hefty returns if the central bank cuts rates.
GeneDx Leads Russell 2000 This Year As It Shifts To More Comprehensive Genetic Testing - Corbus Pharmaceuticals ( NASDAQ:CRBP ) , Candel Therapeutics ( NASDAQ:CADL )
GeneDx Holdings Corp. WGS has made the biggest gains on the Russell 2000 Index in 2024 as the biotechnology company moves toward more comprehensive genetic testing. The Maryland-based company's shares have soared 1,101% so far this year as of midday Thursday, according to Tradingview.
Top Performing Industry ETFs In June: Software Leads Returns, Chipmakers Attract Most Inflows
June closed on a high note for the stock market, with the S&P 500, tracked by the SPDR S&P 500 ETF Trust ( NYSE:SPY ) , gaining 3.2%, despite significant disparities in sector and industry performances.
All Public Company News from PR Newswire
All Public Company PR ...
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SAN DIEGO, June 21, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. ( Nasdaq: RNA ) , a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates ( AOCs™ ) , today announced that on June 20, 2024, the Human Capital Management ...
( RNA ) - Analyzing Avidity Biosciences's Short Interest - Avidity Biosciences ( NASDAQ:RNA )
Avidity Biosciences's RNA short percent of float has fallen 4.33% since its last report. The company recently reported that it has 10.82 million shares sold short, which is 14.81% of all regular shares that are available for trading.
Adobe, Avidity Biosciences And 3 Stocks To Watch Heading Into Friday - Adobe ( NASDAQ:ADBE )
With U.S. stock futures trading mixed this morning on Friday, some of the stocks that may grab investor focus today are as follows: Adobe Inc. ADBE posted upbeat results for its second quarter and also issued a strong forecast.
Avidity Up 33% on Rare Muscle Disease Study Results - Arcutis Biotherapeutics ( NASDAQ:ARQT ) , Heron Therapeutics ( NASDAQ:HRTX )
Avidity Biosciences RNA announced encouraging initial data from the phase I/II FORTITUDE study evaluating two doses of delpacibart braxlosiran ( del-brax, or formerly AOC 1020 ) in facioscapulohumeral muscular dystrophy ( FSHD ) , a rare genetic disease of the muscles.
Avidity ( RNA ) Up 33% on Rare Muscle Disease Study Results
Initial data from an early-stage study shows that treatment with Avidity's (RNA) experimental therapy could address the underlying cause of a rare muscle-weakening condition.
Avidity Biosciences, Inc. Announces Proposed Public Offering of Common Stock
SAN DIEGO, June 12, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. ( Nasdaq: RNA ) , a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates ( AOCs™ ) , today announced that it intends to offer and sell, subject to market and ...
Crude Oil Moves Higher; Vera Bradley Shares Slide - Avidity Biosciences ( NASDAQ:RNA )
U.S. stocks traded higher toward the end of trading, with the S&P 500 surging around 1% on Wednesday. The Dow traded up 0.06% to 38,771.21 while the NASDAQ rose 1.77% to 17,651.35. The S&P 500 also rose, gaining, 1.03% to 5,430.69. Information technology shares jumped by 3% on Wednesday.
Why Avidity Biosciences Shares Are Trading Higher Wednesday - Avidity Biosciences ( NASDAQ:RNA )
Avidity Biosciences RNA stock is moving higher Wednesday following the company's announcement that the Phase 1/2 FORTITUDE trial yielded positive results. The Details: The 39 patient trial was in relation to treating facioscapulohumeral muscular dystrophy ( FSHD ) with delpacibart braxlosiran.
Casey's Reports Upbeat Earnings, Joins Avidity Biosciences, Rentokil Initial And Other Big Stocks Moving Higher On Wednesday - Casey's General Stores ( NASDAQ:CASY )
U.S. stocks were higher, with the Nasdaq Composite gaining over 250 points on Wednesday. Shares of Casey's General Stores, Inc. CASY rose sharply during Wednesday's session after the company reported better-than-expected quarterly financial results. Also, the company increased its quarterly ...
The 'Impressive' Results That Sent This Top 1% Player To A High
Biotech Stock Avidity, A Top 1% Stock, Skyrockets On Promising Muscular Dystrophy Drug Results Investor's Business Daily ...
Avidity Announces Unprecedented AOC 1020 Data from Phase 1/2 FORTITUDE™ Trial Demonstrating Greater Than ... - PR Newswire
Avidity Announces Unprecedented AOC 1020 Data from Phase 1/2 FORTITUDE™ Trial Demonstrating Greater Than ... PR ...
A Glimpse Into The Expert Outlook On Avidity Biosciences Through 6 Analysts
In the last three months, 6 analysts have published ratings on Avidity Biosciences ( NASDAQ:RNA ) , offering a diverse range of perspectives from bullish to bearish. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to ...
2 Potentially High-Reward Growth Stocks to Buy Right Now
These two biotechnology stocks could be gearing up for a run.
Bank of America Predicts up to ~200% Surge for These 2 'Strong Buy' Stocks
New indicators of a cooling economy eased inflation concerns, driving the S&P 500 to record highs last week. The index, which dropped around 4% in April, is now up 11% for the year. Will this momentum continue? Savita Subramanian, head of US Equity and Quantitative strategy at Bank of America, ...
Coherus BioSciences ( CHRS ) Reports Q1 Loss, Misses Revenue Estimates
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -540% and 24.45%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
